Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Burnham P, Chen F, Cheng AP, Srivatana V, Zhang LT, Edusei E, et al. Peritoneal Effluent Cell-Free DNA Sequencing in Peritoneal Dialysis Patients With and Without Peritonitis. Kidney Med. 2022;4(1):100383.

McEachron J, Baqir AW, Zhou N, Jabbar A, Gupta R, Levitan D, et al. Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma. Gynecol Oncol Rep. 2022;39:100918.

Gerber N, Vella A, Racine-Brzostek S, Platt SL. Rapid Absolute Neutrophil Count Testing Guides Targeted Antimicrobial Therapy in Febrile Pediatric Oncology Patients. Pediatr Emerg Care. 2022;38(2):e743-e745.

Tow CY, Castrodad-Rodríguez CA, Panarelli N, Massoumi H. Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period. Transplant Proc. 2022;54(10):2794-2796.

Boyraz B, Agarwal S, Pratt DS, Simoneau T, Bhan I, Markmann JF, et al. Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology. 2022;80(2):450-453.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376(6596):eabe1505.

Lam H, Nguyen F, Wang X, Stock A, Lenskaya V, Kooshesh M, et al. An accessible, efficient, and accurate natural language processing method for extracting diagnostic data from pathology reports. J Pathol Inform. 2022;13:100154.

Magro CM, Mo JH, Kerns MJ. Leukocytoclastic vasculitis in association with linear epidermal basement membrane zone immunoglobulin deposition: Linear vasculitis. Clin Dermatol. 2022;40(6):639-650.

Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, et al. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022;24(8):1404.